Saturday, January 18, 2014

CAMPTEN ! IN NEURO-ENDOCRINE TUMORS!

Somethings make you scratch your head,
and now you wonder what made them think of it...
In life revisiting stuff is not bad after all...
WHO HAD THOUGHT OF THAT
AND THEN IT MAKES YOU RUN BACK TO THE DRAWING BOARD
COMBINATION OF XELODA AND TEMODAR IN NEURO-ENDOCRINE TUMOR?
THE RESULT IS UNEXPECTEDLY GOOD!
WHAT IS THE GENETIC BASIS OF THIS, CRBCM WONDERS!  LET'S GO BACK HERE....THE SEARCH SHOULD NOT BE LONG, I GUESS......to be this effective the mode of action go to be additive which in gene may mean a more total blockade of a specific gene or pathway, or blockade of 2 competing gene/pathways or may be blockade of 1 pathway and its rescue process.  We have got to go deeper.  And why Neuroendocrine ? Is that mean where Etoposide may work such as in the epigenetic area where Histone Deacetylase are king, or is it in the mitochondria where the CREB genes , BCL-2 are in effect.   Xeloda aims a Thymidilate synthase impairing S-phase but what that have to do with silencing th MGMT gene that unleashes Temodar alkylating effect...does blocking synthase and the need in S phase give a better out look...well we need dig in further...and why neuro endocrine, why the hormone? here focus on epigenetic phenomena is warranted...
Post a Comment